Knopp Biosciences

Products and Platforms

• Dexpramipexole in ALS

  Knopp’s most advanced R&D program is the development of dexpramipexole, a novel, oral investigational treatment for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease with limited treatment options.

• Dexpramipexole in Immunology

  Knopp is advancing dexpramipexole as an immunological therapeutic based on its preclinical and clinical activity in modulating white blood cells known as eosinophils.

• Mitochondrial Discovery Platform

  The disruption of cellular bioenergetics has emerged as a common factor in pathways leading to cell death in ALS, Parkinson's, and other neurodegenerative disorders. Knopp is discovering novel small-molecule mediators of these pathways.

• Ion Channel Discovery Platform

  Ion channels, or proteins that regulate the excitability of cells, represent an important class of drug targets in several neurological and cardiovascular conditions. Knopp is discovering novel compounds to modulate these channels.